http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-063302-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| filingDate | 2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f76298cf2d86b63a52e98417cf2521ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20ad4f73c86945c213850117443f0e28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bfd7aec4c7dde4643a1bc5ec1805af7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eddc83839fb8221cafd5243d36129e40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e585618867d29e964cbd4c183fce3f81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ccf39248f93777c3b556131d1927eba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82544364093eb24ddc206690785d3101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_882d3ed926fdf977b48b11c045906b64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4f1cb33296b46b0e589c42293d24d48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1de8057b9292bf2a19a77890788194a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_531720e31f7affa35afd1d0b43ab0671 |
| publicationDate | 2009-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-063302-A1 |
| titleOfInvention | DERIVATIVES OF 4-BENZO [B] TIOFEN-4-IL-PIPERAZIN-1-IL WITH ANTAGONIST ACTION OF THE 5-HT2A SEROTONINE RECEIVER AND ADRENALINE ALFA1 RECEPTOR AND PARTIAL AGRONIST OF THE D2 RECEPTOR, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND UNDERSTANDS TO PRODUCE IT. |
| abstract | A pharmaceutical composition that understands them and a process to produce them. Claim 1: A heterocyclic compound or a salt thereof characterized by the general formula (1) [wherein Q represents a group represented by the following formula R11-C (= Z) N (R12) A1- (wherein A1 represents a lower alkylene group; Z represents O or Si; R11 represents (1-1) hydrogen, (1-2) lower alkyl, (1-3) aryl selected from the group consisting of a phenyl, naphthyl and dihydroindenyl group (wherein the aryl group may be selected by at least one group selected from the group consisting of the following substituents (i) to (xxxiii): (i) lower alkyl, (ii) lower alkenyl, (iii) lower alkyl substituted with halogen, (iv ) lower alkoxy, (v) halogen substituted lower alkoxy, (vi) nitro, (vii) cyano, (viii) halogen, (ix) aryl, (x) aryloxy, (xi) lower alkoxycarbonyl, (xii) hydroxy, ( xiii) protected hydroxy, (xiv) lower alkanoyl, (xv) sulfamoyl, (xvi) lower alkylthio, (xvii) lower alkylsulfonyl, (xviii) hydroxysulfoni lo, (xix) amino which may have groups selected from the group consisting of lower alkyl, lower alkanoyl, C3-8 cycloalkyl, aryl and aroyl, (xx) lower morpholinylcarbonylalkyl, (xxi) morpholinylcarbonylalkyl, (xxii) pyrrolyl, (xxiii ) pyrazolyl, (xxiv) imidazolyl, (xxv) triazolyl, (xxvi) pyridyl, (xxvii) pyrrolidinyl which may have one or more oxo groups, (xxviii) morpholinyl, (xxix) thiomorpholinyl, (xxx) lower alkynyl, (xxxi) C3-8 cycloalkyl, (xxxii) guanidino and (xxxiii) dihydropyrazzolyl which may have 1 or several groups selected from the group consisting of an oxo group and a lower alkyl group), (1-4) a heterocyclic group (wherein the group heterocyclic may be selected by at least one group selected from the group consisting of the following substituents (i) to (xix): (i) lower alkyl, (ii) lower alkyl substituted with halogen, (iii) lower alkoxy, (iv) lower alkoxy substituted with halogen, (v) halogen, ( vi) aryl which may have, in the aryl group, a group selected from the group consisting of halogen and a lower alkyl substituted with halogen, (vii) lower arylalkyl which may have halogen atoms, (viii) lower alkanoyl, (ix) aroyl, (x) lower aminoalkanoyl which may have, in the amino group, a lower alkanoyl group, (xi) lower alkylthio, (xii) pyrrolyl, (xiii) oxo, (xiv) thioxo, (xv) carbamoyl, (xvi) hydroxy, (xvii) pyranyl, (xviii) thienyl and (xix) furyl, (1-15) a lower aminoalkyl group which may have, in the amino group and / or the lower alkyl group, a group or groups selected from the group that it consists of a lower alkyl, lower alkanoyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower carbamoylalkyl, indolylcarbonyl, aryl group (the aryl group may have a group or groups selected from the group consisting of halogen and a lower alkoxy group) and lower arylalkoxycarbonyl, ( 1-6) lower alkoxy-lower alkyl , (1-7) lower aroylalkyl, (1-8) lower arylalkyl which may have, in the aryl group, a group or groups selected from the group consisting of a lower alkyl, lower alkoxy, hydroxy, halogen and a nitro group , (1-9) lower aryloxyalkyl which may have, in the aryl group, a group selected from the group consisting of a lower alkyl, lower alkoxy, halogen and a cyano group, (1-10) lower adamantyl alkyl, (1- 11) lower arylalkenyl which may have, in the aryl group, a group selected from the group consisting of a lower alkyl group, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, amino which may have a group or alkyl groups lower, halogen and a nitro group, (1-12) C3-8 cycloalkyl which may have a group or groups selected from the group consisting of: amino that may have a lower alkyl group or groups, lower aminoalkyl that may have a group or alkyl groups in ferior, and aryl which may have a group selected from the group consisting of halogen and lower alkyl, (1-13) C3-8 cycloalkyl-lower alkyl, (1-14) lower arylthioalkyl, (1-15) lower alkyl substituted with a heterocyclic group selected from the group consisting of piperidyl, tetrahydropyranyl, pyridyl, thienyl, imidazolyl, tetrazolyl, benzimidazolyl, isoindolyl, thiazolidinyl and an indolyl group (wherein the heterocyclic group may have a group or groups selected from the group consisting of a group lower alkyl, lower alkoxy, halogen, oxo and thioxo), (1-16) lower arylalkenyl (which may have, in the lower alkenyl group, aryl), (1-17) lower alkenyl substituted with a heterocyclic group selected from the group that it consists of benzodioxolyl, pyridyl, furyl and an imidazolyl group, (1-18) a lower benzodioxoliloxyalkyl group, (1-19) lower pyridylthioalkyl, or (1-20) amino which may have a lower alkyl group or groups; and R12 represents (2-1) hydrogen, (2-2) lower alkyl, (2-3) lower alkyl substituted with halogen, (2-4) lower alkenyl, (2-5) lower alkynyl, (2-6) lower alkanoyl, (2-7) lower hydroxyalkyl, (2-8) lower alkoxy-lower alkyl, (2-9) C3-8 cycloalkyl, (2-10) C3-8 cycloalkyl-lower alkyl, (2-11) aryl, (2-12) lower arylalkyl which may have, in the aryl group, a group selected from the group consisting of an amino group that may have a lower alkyl group or groups and an aryloxy group, (2-13) tetrahydrofuryl, (2-14) lower alkyl substituted with a heterocyclic group selected from the group consisting of a furyl group and a pyridyl group, (2-15) tetrahydropyranyl, or (2-16) lower alkanoyloxy-lower alkyl), or a group represented by the following general formula R21-A2- (where -A2- represents lower alkylene, lower alkenylene or a group -A21-O-A22-, where A21 and A22 are the same or different and each represents alq C1-5 uylene, (with the proviso that a total number of C atoms constituting the alkylene group of A21 and the alkylene group of A22 does not exceed 6); and R21 represents an N-containing heterocyclic group, wherein the N-containing heterocyclic group represented by R21 may be selected by at least one group selected from the group consisting of the following points (1) to (13): (1) alkyl lower halogen substituted or unsubstituted, (2) lower alkenyl, (3) lower alkoxy, (4) hydroxy, (5) protected hydroxy, (6) aryl, (7) lower alkanoyl, (8) carboxy, (9) lower alkoxycarbonyl, (10) carbamoyl which may have a lower alkyl group or groups, (11) lower arylalkyl (which may have, in the aryl group, a lower alkoxy group or groups) (12) oxo and (13) thioxo)] . |
| priorityDate | 2006-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.